Author:
Patel Shruti, ,Patel Asha
Abstract
For the treatment of lung cancer, erlotinib is used as primary treatment. Erlotinib is an epidermal growth factor receptor inhibitor, however it is deposited in normal cells also and clinicians do not prefer it. This constraint opens the way for development of targeted therapy. Mixed micelles via self-assembly have the functionality to improve the delivery of hydrophobic drugs, and improve the pharmacokinetics of the loaded drug. Pluronic® F127 and tocopheryl polyethylene glycol succinate were used to prepare micelles. BoxBehnken design was applied to optimize formulation. With optimum ratio, micelles were characterized, and pharmacokinetic parameters were predicted. Design batches F1 to F15, showed the range of 42-133 nm size and 55-82 % of entrapment. Critical micelles concentration was found to be 3 × 10-5 M. Drug release of optimized mixed micelles was found 84.91± 1.58 % in 72 h. In a nutshell, self-assembled mixed micelles would be a suitable delivery platform for targeting anticancer agents.
Publisher
Indian Drug Manufacturers' Association (IDMA)
Subject
Drug Discovery,Pharmaceutical Science,Pharmacology
Reference27 articles.
1. 1. Tisdale M. J.: Alkylating analogues of the tumour inhibitor 5-aziridino-2,4-dinitrobenzamide, Chem. Biol. Interact., 1971, 3(2), 95-107.
2. 2. Latimer K.M. and Mott T.F.: Lung cancer: Diagnosis, treatment principles, and screening, Am Fam. Physician., 2015, 91(4), 250-256.
3. 3. Oikawa T., Ohira T., Otani K., Hagiwara M., Konaka C. and Ikeda N.: Clinical usefulness of gefitinib for non-small-cell lung cancer with a double epidermal growth factor receptor mutation, Mol. Clin. Oncol., 2015, 3(2), 329-333.
4. 4. Levitzki A. and Klein S.: Signal transduction therapy of cancer, Mol. Aspects Med., 2010, 31(4), 287-329.
5. 5. Yang K.M., Shin I.C., Park J.W., Kim K.S., Kim D.K. and Park K.: Nanoparticulation improves bioavailability of erlotinib, Drug Dev. Ind. Pharm., 2017, 43(9), 1557-1565.